Grabels, France, February 26, 2025 – Mabqi, a biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer, today announced that it has obtained €5 million in funding from the French government under the Innovations in Biotherapies and Bioproduction call for projects under of the France 2030 program operated on behalf of the French government by Bpifrance.
Mabqi develops a first-in-class MQI-201 antibody that specifically targets TRPV6 ion channel, an innovative therapeutic target in oncology involved in the development of several cancers with high medical need, including prostate cancer. This funding will enable Mabqi to launch the bioproduction of this antibody, to carry out all the regulatory preclinical stages and to conduct an initial Phase 1a clinical study, which is scheduled to start early 2027. To know more
